Zaki Hasan

تحويل رعاية الأطفال من خلال الابتكار الصحي. 🌍💉

[Jianing Yue_Vas Surg in Shanghai @yuejianing]

It was a great honor to share our work on infected abdominal aorta at the PANGU Aortic Forum in Shanghai. I also really enjoyed the excellent presentations by Prof. Coselli @JCoselli_MD and Prof. Oshima @SusumuOshima and other cardiac surgery colleagues, and learned a great deal from them. #AortaEd

[NEJM @NEJM]

Among children with septic shock, whether treatment with balanced crystalloid fluid leads to better outcomes than a crystalloid such as 0.9% saline is unclear. Research findings are summarized in a new Quick Take video. https://t.co/fj8gAbvnzm

[Ella Marushchenko @Ella_Maru]

Human 3D Neurovascular Platform 🫀+ 🧠
My new cover illustrates a long-lived human 3D neurovascular PENTA-culture (5 components) platform composed of a biomimetic silk scaffold and
1 - neurons
2 - astrocytes
3 - microglia
4 - brain microvascular endothelial cells
5 - pericytes

The model uniquely supports sustained cellular stability and vascular-like interconnected networks with barrier-like function, enabling mechanical injury studies in a human-relevant multicellular brain microenvironment.

💜 Congratulations to Daniel Hinrichsen and a whole team!

[Cris Muñoz-Pinedo & Ernest Nadal - PRETT lab @apoptosislab]

Tumors steal a signal from T cells | Science

Navdeep Chandel on the study about tumor secretion of the extracellular antioxidant peroxiredoxin 1 that prevents TCR activation
https://t.co/bMEJrH4FV6

[Henry Han @HanCardiomd]

#Metoprolol in #COPD without #CVD — does it prevent exacerbations?
Multicenter, open-label, pragmatic phase 4 RCT | n=1,695

📍Metoprolol vs standard care
📍 Primary composite: COPD exacerbation, CV event, or death at 1 year
📍 Primary endpoint: 27% vs 30%
📍 HR 0.87 (95% CI 0.73–1.05), P=0.14

No significant reduction in:

📌COPD exacerbations: HR 0.88 (95% CI 0.72–1.06)
📌CV events: HR 0.73 (95% CI 0.48–1.11)
📌Death: HR 0.92 (95% CI 0.48–1.77)
📌🏥 COPD exacerbations: HR 0.87 (95% CI 0.58–1.28)

@NEJM https://t.co/ie8bxNoNMp @DrMarthaGulati @mmamas1973 @cpgale3 @pabeda1 @Hragy

[chadi nabhan MD, MBA, FACP @chadinabhan]

This week's #HealthcareUnfiltered tackled Healthcare Delivery as the co-founder of Zoomlogi joined the show to share how AI and innovation are solving for this problem.
How can we assure and optimize patients getting their life-saving therapies on time?
https://t.co/mCfZsFfYEg

[Aakash Desai @ADesaiMD]

✅ Two years of clinic by day, finance problem sets by night.

🎓 MBA (Finance) complete.

Every therapy I prescribe survived a market analysis and a go/no-go before it survived a phase 1. The clinic and the boardroom need translators. Hoping to contribute at that intersection!

[Dr Alo, DO, FACC @MohammedAlo]

Cardiologist: Lipoprotein a trial on Pelacarsen did not reduce MACE. No difference between the group that received the medication and the group that did not receive the medication. In one way this is good news because it shows us that if you control your LDL cholesterol and get

[SynBioBeta @SynBioBeta]

Cime Therapeutics has joined Lilly TuneLab, gaining access to AI/ML models trained on decades of Lilly research data. Cime will pair the models with its automated synthesis and direct-to-biology platform to accelerate early drug discovery.

https://t.co/XvpNfPSexr

Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R

[chadi nabhan MD, MBA, FACP @chadinabhan]

Looking forward to the Chicago second annual BGTs in Solid Cancers. We will discuss relevant BGTs that have clinical implications & those to watch for from research perspective. #BGT2026
@BalazsHalmosMD @BrainTumorDoc @cancerassassin1 @Dr_R_Kurzrock @shilpaonc @karima_oualla

[The ASCO Post @ASCOPost]

📽 The latest news in #AI & #oncology:

🔹 CE certification for autonomous AI in #BreastCancer screening
🔹 ML-designed individualized therapy in #Melanoma
🔹 AI agent for clinical decision support in #BloodCancers

#ASCOAI’s Weekly News Brief: https://t.co/rF0LuyaC4z

[Epilepsia @EpilepsiaJourn]

The Five Sign is a reproducible ictal hand semiology preferentially associated with insulo-opercular epilepsy.
https://t.co/i3Ty1aCvK5

#epilepsy #ilae #epilepsia #elementarymotorsign #epilepticsemiology #handposturesandmovements #insuloopercularepilepsy #preoperativeevaluation

[Ahmed Bennis MD 🫀 @drbennisahmed]

Generic ARNI could change the economics of HFmrEF/HFpEF 💊💰

At a generic sacubitril/valsartan price of $12.75/month, the numbers become striking:

🔹 Overall HFmrEF/HFpEF: 17.5 HF hospitalizations prevented/1,000 patient-years → $81,800 net savings

🔹 Recent worsening HF (<30 days): 58.9 hospitalizations prevented/1,000 patient-years → $637,300 net savings

Hospitalization cost offsets exceed drug costs by 1.5× overall and 5.2× after recent worsening HF.

👉 When ARNI becomes inexpensive, preventing HF admissions may make it not only clinically valuable—but cost-saving, especially in high-risk patients.

#HeartFailure #HFpEF #HFmrEF #ARNI #SacubitrilValsartan #Cardiology #HealthEconomics #GDMT

[Gavi, the Vaccine Alliance @gavi]

When an mpox outbreak strikes, countries need rapid access to vaccines that can help to stop the disease in its tracks.

Enter: the launch of a global mpox vaccine stockpile, which aims to give all countries worldwide faster and more predictable access to mpox vaccines when outbreaks occur.

Here’s how this new global initiative will work: https://t.co/NC7W2xTxh7

[Pam R. Taub, MD❤️💃🏻 @PamTaubMD]

Lp(a)HORIZON topline results: pelacarsen lowered Lp(a) but did not reduce cardiovascular events, in a trial where background risk was exceptionally well controlled (mean LDL-C around 66 mg/dL).
https://t.co/FFoZ5dX1nU
There are many lessons here for future trials. Clinically, not all Lp(a) elevation is created equal. We need to know whether isoform differences drive risk and personalize management accordingly.

Lp(a) also does not act in isolation. As we argued in our European Heart Journal editorial "Two to Tango" (https://t.co/FXKxVqRGnX), it is the interplay among risk factors that ultimately leads to cardiovascular events. Many researchers have shown that controlling modifiable risk factors substantially lowers risk in patients with elevated Lp(a), so knowing your number remains a powerful driver of prevention, even without a targeted therapy.
This result changes nothing about the enormous burden of Lp(a) or the case for universal screening and public education. It sharpens the questions we must answer: who is at greatest risk, why, and how best to protect them. Preventive cardiology owes a great deal to Lp(a). It has unlocked the potential of prevention and CV risk modification. @hsbhatia @CMichaelGibson @MWilkinsonMD @DrMarthaGulati @DavidLBrownMD @kaulcsmc @RonBlankstein @Drroxmehran @DrEugeneYang @ProfKausikRay @VietHeartPA @drpablocorral @JohnKastelein @CBallantyneMD @Drroxmehran @escardio @ACCinTouch @hmkyale @ASPCardio @AnnMarieNavar @DrMichaelShapir @mdavidsonmd @EugeniaGianos @BudoffMd @MattRamsisMD @pnatarajanmd @EricTopol @EricAdler17 @society_eas

[Bartosz Hudzik MD PhD FESC FACC @BartoszHudzik]

HORIZON challenges therapeutic reversibility, not necessarily Lp(a) causality: Mendelian randomization reflects lifelong exposure, whereas pharmacologic intervention tests whether late-life lowering changes outcomes https://t.co/oWDfdegdvN @ErinMichos @mmamas1973 @CMichaelGibson

[MV Chandrakanth @ChandrakanthMv]

Can we prevent recurrence in early-stage RET+ NSCLC? 🎯

LIBRETTO-432 | Phase 3 | NEJM 2026

In patients with stage II–IIIA RET fusion–positive NSCLC after curative-intent therapy, adjuvant selpercatinib delivered:

🔹 83% ↓ risk of recurrence, progression, or death
🔹 2-year EFS: 92% vs 61%
🔹 Recurrence: 7% vs 35%

The trade-off: Grade ≥3 AEs 67% vs 24%, while OS remains immature.

EGFR → ADAURA
ALK → ALINA
RET → LIBRETTO-432

Targeted therapy is moving earlier.

Wu Y-L et al. N Engl J Med. 2026;395:660–670.
DOI: 10.1056/NEJMoa2602628

#LungCancer #NSCLC #RET #Selpercatinib #Oncology #MVONCO

[The ASCO Post @ASCOPost]

⏰ Long-term COMBI-I results show a survival benefit with spartalizumab + dabrafenib/trametinib in BRAF V600–mutant metastatic #Melanoma.

➡️ OS after 5+ years follow-up = 61.5 vs 41.6 months with targeted therapy alone

🔹Antoni Ribas, MD | @JCO_ASCO
🔗 https://t.co/tUPC2UAdQK

[Oncology Tube @oncologytube]

WATCH: Padcev + Keytruda — cisplatin-eligible MIBC 💧
👉 https://t.co/rpHFi0nok1
🔹 July 10, 2026 FDA (KEYNOTE-B15 / EV-304, N=808)
🔹 EFS NR vs 48.5 mo vs gem/cis (HR 0.53)
🔹 OS NR vs NR (HR 0.65); pCR 55.8% vs 32.5%
Perioperative EV + pembro vs neoadjuvant chemo. Video on the page.

@NEJM @pfizer @Merck @ASCO @myESMO @ASCOPost @JCO_ASCO @AstellasUS @OncLive @DrChoueiri @OncoAlert @FDAOncology @urotoday @UrologyTimes @montypal @VJOncology @TargetedOnc @PGrivasMDPhD @neerajaiims @tompowles1 @DrYukselUrun @OncoDaily @SuyogCancer @US_FDA @shilpaonc @TiansterZhang @Uromigos @LauraBukavinaMD @dr_yakupergun @BladderCancerUS @PCF_Science @zklaassen_md @AndreaNecchi @OncoBellmunt @docjavip @nataliagandur @DrKarineTawagi @katy_beckermann @GUOncologyNow @mouwlab @bergsa83 @Dr_Aggen

#Padcev #MIBC #KEYNOTEB15 #EV304 #BladderCancer #FDA

[GutMicrobiota Health @GMFHx]

Gut microbiota generate dinitrosyl iron complexes with cardiometabolic benefits

These new findings shed light on new ways to harness the gut microbiota to support cardiometabolic health

https://t.co/3MqhbK3u8p